RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. (RANI) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (2.9) | C (2.2) | C+ (2.8) | D+ (1.6) | C+ (2.6) | C (2.4) |
| 2026-11-07 | B- (2.9) | D+ (1.7) | C+ (2.8) | C- (1.9) | C+ (2.7) | C (2.4) |
| 2026-10-31 | B- (2.9) | D+ (1.7) | C+ (2.8) | C- (2.0) | C+ (2.7) | C (2.4) |
| 2026-10-24 | B- (2.9) | D+ (1.7) | C+ (2.8) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-10-17 | B- (2.9) | D+ (1.7) | C+ (2.8) | C+ (2.8) | C+ (2.6) | C+ (2.6) |